Skip to content
Sanjivani Paranteral logo

Sanjivani Paranteral

531569 BSE
₹173.55

Close ·

P/E
28.54
View as Markdown
MCP
Close 4 Nov 2026 ₹173.55 −35.30 −16.9% 1Y
Start ₹208.85

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures at the close · EPS basis: Consolidated · TTM

ROCE
18.00%
Debt to Equity
0.30
EPS (TTM)
₹6.08
Book Value
₹39.28
Market Cap
—
P/E (TTM)
28.54
P/B
4.42
ROE
15.70%
Dividend Yield
0.30%
EBITDA
₹11.30 Cr
52W High
₹244.00
52W Low
₹126.00

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

41 Weak

Data confidence 98/100

Category scores

Quality
28
Poor
Returns, margins, earnings quality 22% weight
Valuation
35
Poor
Cheap vs sector & own history 24% weight
Growth
43
Weak
Sales & profit trajectory 9% weight
Financial Health
61
Good
Solvency, leverage, coverage 9% weight
Momentum
64
Good
Trend strength, vol-adjusted 12% weight
Ownership
44
Weak
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

No strengths listed

Weaknesses

3
  • Promoter holding is low: 31.6%
  • Company might be capitalizing the interest cost
  • Debtor days have increased from 66.8 to 82.0 days.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBullish469
OscillatorsBearish261
Moving AveragesStrong Bullish208

Key readings

RSI (14)
52.16
Neutral
MACD (12,26,9)
−1.48
Bullish
SMA (50)
176.32
Bearish
SMA (200)
168.36
Bullish

As of

Growth Rate

From the financial statements below. 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
1Y−2.04%
TTM+4.28%

Net profit

Net profit growth by window
1Y−17.31%
TTM−8.13%

Operating cash flow

Operating cash flow growth by window
1YTurned negative
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
1Y+0.23 pp
TTM+0.98 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2024₹54.41 Cr
Mar 2025₹70.10 Cr
Mar 2026₹68.67 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2024₹6.17 Cr
Mar 2025₹8.09 Cr
Mar 2026₹6.69 Cr

Quarterly Results

₹ Cr
531569 quarterly results, ₹ crore
Particulars Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
14.96
12.86
16.44
18.13
17.35
18.18
17.89
15.5
22.06
13.21
23.84
Expenses
12.99
10.7
14.1
15.28
14.8
15.57
15.25
13.25
18.22
11.64
19.67
Operating Profit
1.97
2.16
2.34
2.85
2.55
2.61
2.64
2.25
3.84
1.57
4.17
OPM %
13.17%
16.8%
14.23%
15.72%
14.7%
14.36%
14.76%
14.52%
17.41%
11.88%
17.49%
Other Income
0.25
0.05
0.09
0.39
0.31
0.43
0.04
0.16
0.3
0.6
0.15
Interest
0.08
0.09
0.02
0.18
0.19
0.2
0.22
0.05
0.21
0.31
0.35
Depreciation
0.24
0.24
0.13
0.15
0.16
0.18
0.16
0.17
0.23
0.66
0.65
PBT
1.9
1.88
2.28
2.91
2.51
2.66
2.3
2.19
3.7
1.2
3.32
Tax %
13.16%
33.51%
24.56%
21.31%
24.3%
17.29%
24.78%
25.11%
24.86%
55%
25%
Net Profit
1.65
1.26
1.71
2.3
1.9
2.19
1.73
1.64
2.78
0.55
2.49
EPS (₹)
1.65
1.08
1.46
1.97
1.6
1.84
1.43
1.34
2.26
0.45
2.03

Profit & Loss

₹ Cr
531569 profit and loss, annual, ₹ crore
Particulars Mar 2024Mar 2025Mar 2026TTM
Sales
54.41
70.1
68.67
74.61
Expenses
46.18
59.76
58.38
62.78
Operating Profit
8.23
10.34
10.29
11.83
OPM %
15.13%
14.75%
14.98%
15.86%
Other Income
0.52
1.22
0.97
1.21
Interest
0.25
0.59
0.65
0.92
Depreciation
0.93
0.62
1.22
1.71
PBT
7.57
10.35
9.39
10.41
Tax %
18.63%
21.84%
28.75%
—
Net Profit
6.17
8.09
6.69
7.46
EPS (₹)
5.28
6.81
5.45
6.08
Div. Payout %
0%
7.34%
0%
—

Balance Sheet

₹ Cr
531569 balance sheet, annual, ₹ crore
Particulars Mar 2024Mar 2025Mar 2026
Equity Capital
11.68
11.88
12.28
Reserves
16.22
26.11
35.96
Borrowings
0.97
8.14
14.28
Other Liabilities
14.53
32.07
25.46
Total Liabilities
43.4
78.2
87.98
Fixed Assets
9.94
20.64
47.34
CWIP
0
19.11
1.15
Investments
0
0
0.73
Other Assets
33.46
38.45
38.76
Total Assets
43.4
78.2
87.98

Cash Flow

₹ Cr
531569 cash flow, annual, ₹ crore
Particulars Mar 2024Mar 2025Mar 2026
Operating
−10.7
12.4
−0.11
Investing
−12.21
−21.91
−9.97
Financing
23.16
10.46
9.84
Net Cash Flow
0.24
0.94
−0.24
Free Cash Flow
−14
−17.95
−10.18
CFO/OP
−117
133
20

Ratios

531569 financial ratios, annual
Particulars Mar 2024Mar 2025Mar 2026
Debtor Days
31.53
86.85
82.01
Inventory Days
125
94.77
91.17
Days Payable
73.56
138
30.61
Cash Conversion Cycle
82.67
44.11
143
Working Capital Days
35.55
−0.1
45.98
ROCE %
—
28.46%
17.96%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Sanjivani Paranteral insights

65 extracted metrics across FY10–FY27.

Shareholding Pattern

As of Sep 2026

  • Public 50.50%
  • Promoters 31.56%
  • Others 13.03%
  • DIIs 4.90%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Sanjivani Paranteral

What does Sanjivani Paranteral Ltd do?
Incorporated in 1994, Sanjivani Parenteral Ltd is a research-based and export-oriented pharmaceutical company
Where is Sanjivani Paranteral Ltd (SANJIVIN) listed?
Sanjivani Paranteral Ltd trades under code 531569 on the BSE.
Which sector does Sanjivani Paranteral Ltd belong to?
Sanjivani Paranteral Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Sanjivani Paranteral Ltd?
Sanjivani Paranteral Ltd trades at a PE ratio of 28.54 as of 4 Nov 2026, on earnings per share of ₹6.08, against a book value of ₹39.28 per share.
What is the 52-week high and low of Sanjivani Paranteral Ltd?
Over the last 52 weeks Sanjivani Paranteral Ltd has traded between ₹126 and ₹244 as of 4 Nov 2026.
Does Sanjivani Paranteral Ltd pay dividends?
Sanjivani Paranteral Ltd has a dividend yield of 0.30%.
What is the Return on Equity (ROE) of Sanjivani Paranteral Ltd?
Sanjivani Paranteral Ltd reported a return on equity of 15.70%. Its debt-to-equity ratio is 0.30.

Company Information

Incorporated in 1994, Sanjivani Parenteral Ltd is a research-based and export-oriented pharmaceutical company

Website sanjivani.co.in
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/531569.md for Sanjivani Paranteral Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month